Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q3 FY2025 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation, Feb 13, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
Date:13.02.2025 To, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations an
Slide 2: Branded IPR-driven Pharma Player in Frontier Markets
Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 4: Contents
Contents 04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap 3
Slide 5: Bridging the Supply Gap in Frontier Markets
Bridging the Supply Gap in Frontier Markets Branded IPR-based pharma Presence in OTC segments including company strong branded generics portfolio Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast portfolio across diverse Backed by deep distributi
Slide 6: Successful Produce, Stock, Sell Business Model
Successful Produce, Stock, Sell Business Model Established operations: Guatemala (Latin America), Dominican Republic (Caribbean) and Expansion initiated: Markets Angola (Africa) Ecuador, Chile (Latin America) New operations: Hondurus, El Salvador,and Nicaragua 897 product registrations in Seven coun
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to ‘Asset Right’
Slide 9: Investment in Manufacturing Facilities
Investment in Manufacturing Facilities Setting up its first pharmaceutical formulation manufacturing unit General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Plant Commissioning by the Q1 o
Slide 10: Global Footprint
Global Footprint Portugal China Existing Market Dominican Republic India Targeted Expansion Guatemala Honduras Product Sourcing Regions El Salvador Nicaragua Ecuador Angola Chile Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9
Slide 11: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 12: Corporate Structure
Corporate Structure Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Balaxi Healthcare Balaxi Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Healthcare Nicaragua Angola LDA C
Slide 13: Experienced Board of Directors
Experienced Board of Directors Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi exp
Slide 14: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 15: Financial Highlights
FINANCIAL HIGHLIGHTS MIM emg Balaxi
Slide 16: Management's Comments
Management’s Comments “In Q3 FY25, through our strategic efforts to strengthen the distribution network, expand sales channels, and enhance our presence in key sectors such as hospital across Angola, we observed a notable recovery in that market. Despite challenges in Dominican Republic and Guatemal
Slide 17: Quarterly Financial Performance (Consolidated)
Quarterly Financial Performance (Consolidated) Particulars (INR Crore) Q3 FY25 Q3 FY24 YoY Revenue 73.29 60.78 20.58% Gross Profit 29.45 30.42 (3.19%) Gross Margin % 40.19% 50.05% (987 bps) EBITDA before exceptional item* 7.93 13.53 (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (11
Slide 18: Pharma Product Mix – Q3 FY25
Pharma Product Mix – Q3 FY25 Geographies Products Shareholders’ Debt Fixed Assets Working Capital 37% Funds Africa* 41% Branded LATM** Generics 63% 59% Dosage Forms Therapeutic Areas 11% Tablets Antibiotics 36% 16% Injectables Analgesic 42% 44% Liquids Anti-malaria Capsules Others 14% Others 6% 16%
Slide 19: Financial Performance (Consolidated): FY24
Financial Performance (Consolidated): FY24 Particulars (INR Crore) FY24 FY23 YoY Revenue 241.29 336.43 (28.3%) Gross Profit 112.61 134.01 (16.0%) Gross Margin % 46.7% 39.8% +690 bps EBITDA 5.79 59.17 (90%) EBITDA Margin % 2.40% 17.6% -1520bps Profit After Tax (2.39) 45.96 - PAT Margin % - 13.7% - Ea
Slide 20: Pharma Product Mix – FY24
Pharma Product Mix – FY24 Geographies Products Shareholders’ Debt Fixed Assets Working Capital Funds 36% 47% Africa* Branded 53% LATAM** Generics 64% Dosage Forms Therapeutic Areas 14% Tablets Antibiotics 34% 46% Injectables Analgesic 16% 43% Liquids Anti-malaria Capsules Others 12% Others 6% 16% 15
Slide 21: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel Balaxi in 2020: Business Consolidation Presence across Angola, Guatemala and Dominican Republic Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-24: Expansion into New Geographies Aim to cap
Slide 22: Thank You
Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact Sunny Purohit +91-40-2355-5300 sunny@balaxi.com www.balaxipharma.in BALAXI Thank You BALAXI:IN
Balaxi Pharmaceuticals — Q3 FY2025 Earnings Presentation on 6ix